Enhanced eryptosis contributes to anemia in lung cancer patients

Oncotarget

Volumn 7, Issue 12, 2016, Pages 14002-14014

  Bissinger, Rosi ^a   Schumacher, Carla ^a   Qadri, Syed M ^b   Honisch, Sabina ^a   Malik, Abaid ^a   Götz, Friedrich ^a   Kopp, Hans Georg ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anemia; Carcinoma; Cell shrinkage; Ceramide; Eryptosis

Indexed keywords

CALCIUM ION; CARBOPLATIN; CERAMIDE; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; HEMOGLOBIN; LIPOCORTIN 5; NAVELBINE; PEMBROLIZUMAB; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE; TOPOTECAN; ANTINEOPLASTIC AGENT; CALCIUM;

ADULT; AGED; ANEMIA; ARTICLE; CALCIUM CELL LEVEL; CELL DEATH; CELL VOLUME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYPTOSIS; ERYTHROCYTE; FEMALE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MIDDLE AGED; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RETICULOCYTE COUNT; RETICULOCYTOSIS; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; VERY ELDERLY; ADENOCARCINOMA; CANCER STAGING; CASE CONTROL STUDY; CELL SIZE; COMPLICATION; FOLLOW UP; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL SIZE; CERAMIDES; ERYPTOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXIDATIVE STRESS; PHOSPHATIDYLSERINES; PROGNOSIS; REACTIVE OXYGEN SPECIES; SMALL CELL LUNG CARCINOMA;

EID: 84971663768     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7286     Document Type: Article

References (51)

1. Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2008:159-165.
2. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990; 322: 1689-1692.
3. Park S, Jung CW, Kim K, Kim SJ, Kim WS, Jang JH. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. Oncotarget. 2015; 6: 42803-42812. doi: 10.18632/oncotarget.5658.
4. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316: 73-78.
5. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007; 109: 4038-4044.
6. Qadri SM, Mahmud H, Lang E, Gu S, Bobbala D, Zelenak C, Jilani K, Siegfried A, Foller M, Lang F. Enhanced suicidal erythrocyte death in mice carrying a loss-of-function mutation of the adenomatous polyposis coli gene. J Cell Mol Med. 2012; 16: 1085-1093.
7. Hirsh V. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2014; 14: 129-141.
8. Yang X, Yang K, Kuang K. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. Curr Oncol Rep. 2014; 16: 390.
9. Lang E, Qadri SM, Lang F. Killing me softly - suicidal erythrocyte death. Int J Biochem Cell Biol. 2012; 44: 1236-1243.
10. Lang F, Qadri SM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif. 2012; 33: 125-130.
11. Kriebardis AG, Antonelou MH, Stamoulis KE, Economou-Petersen E, Margaritis LH, Papassideri IS. Progressive oxidation of cytoskeletal proteins and accumulation of denatured hemoglobin in stored red cells. J Cell Mol Med. 2007; 11: 148-155.
12. Tesoriere L, Attanzio A, Allegra M, Cilla A, Gentile C, Livrea MA. Oxysterol mixture in hypercholesterolemia-relevant proportion causes oxidative stress-dependent eryptosis. Cell Physiol Biochem. 2014; 34: 1075-1089.
13. Zidova Z, Kapralova K, Koralkova P, Mojzikova R, Dolezal D, Divoky V, Horvathova M. DMT1-mutant erythrocytes have shortened life span, accelerated glycolysis and increased oxidative stress. Cell Physiol Biochem. 2014; 34: 2221-2231.
14. Foller M, Mahmud H, Gu S, Kucherenko Y, Gehring EM, Shumilina E, Floride E, Sprengel R, Lang F. Modulation of suicidal erythrocyte cation channels by an AMPA antagonist. J Cell Mol Med. 2009; 13: 3680-3686.
15. Klarl BA, Lang PA, Kempe DS, Niemoeller OM, Akel A, Sobiesiak M, Eisele K, Podolski M, Huber SM, Wieder T, Lang F. Protein kinase C mediates erythrocyte "programmed cell death" following glucose depletion. Am J Physiol Cell Physiol. 2006; 290: C244-C253.
16. Lang E, Gatidis S, Freise NF, Bock H, Kubitz R, Lauermann C, Orth HM, Klindt C, Schuier M, Keitel V, Reich M, Liu G, Schmidt S, et al. Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology. 2014.
17. Attanasio P, Bissinger R, Haverkamp W, Pieske B, Wutzler A, Lang F. Enhanced suicidal erythrocyte death in acute cardiac failure. Eur J Clin Invest. 2015; 45: 1316-1324. doi: 10.1111/eci.12555.
18. Lupescu A, Bissinger R, Goebel T, Salker MS, Alzoubi K, Liu G, Chirigiu L, Mack AF, Qadri SM, Lang F. Enhanced suicidal erythrocyte death contributing to anemia in the elderly. Cell Physiol Biochem. 2015; 36: 773-783.
19. Souma T, Suzuki N, Yamamoto M. Renal erythropoietin-producing cells in health and disease. Front Physiol. 2015; 6: 167.
20. Myssina S, Huber SM, Birka C, Lang PA, Lang KS, Friedrich B, Risler T, Wieder T, Lang F. Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol. 2003; 14: 2750-2757.
21. Foller M, Kasinathan RS, Koka S, Huber SM, Schuler B, Vogel J, Gassmann M, Lang F. Enhanced susceptibility to suicidal death of erythrocytes from transgenic mice overexpressing erythropoietin. Am J Physiol Regul Integr Comp Physiol. 2007; 293: R1127-1134.
22. Sheikh S, Littlewood TJ. Erythropoiesis-stimulating agents for anemic patients with cancer. Expert Rev Hematol. 2010; 3: 697-704.
23. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91: 2214-2221.
24. Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009; 14: 43-56.
25. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116: 11S-26S.
26. Thomas GM. Raising hemoglobin: an opportunity for increasing survival? Oncology. 2002; 63:19-28.
27. Milonski J, Zielinska-Blizniewska H, Olszewski J, Majsterek I, Mrowicka M. DNA damage and oxidant-antioxidant status in blood of patients with head and neck cancer. DNA Cell Biol. 2015; 34: 213-219.
28. Goldkorn T, Chung S, Filosto S. Lung cancer and lung injury: the dual role of ceramide. Handb Exp Pharmacol. 2013:93-113.
29. Alzoubi K, Calabro S, Bissinger R, Abed M, Faggio C, Lang F. Stimulation of suicidal erythrocyte death by artesunate. Cell Physiol Biochem. 2014; 34: 2232-2244.
30. Arnold M, Bissinger R, Lang F. Mitoxantrone-induced suicidal erythrocyte death. Cell Physiol Biochem. 2014; 34: 1756-1767.
31. Bissinger R, Fischer S, Jilani K, Lang F. Stimulation of erythrocyte death by phloretin. Cell Physiol Biochem. 2014; 34: 2256-2265.
32. Jacobi J, Lang E, Bissinger R, Frauenfeld L, Modicano P, Faggio C, Abed M, Lang F. Stimulation of erythrocyte cell membrane scrambling by mitotane. Cell Physiol Biochem. 2014; 33: 1516-1526.
33. Lupescu A, Bissinger R, Herrmann T, Oswald G, Jilani K, Lang F. Induction of suicidal erythrocyte death by novobiocin. Cell Physiol Biochem. 2014; 33: 670-680.
34. Lupescu A, Bissinger R, Warsi J, Jilani K, Lang F. Stimulation of erythrocyte cell membrane scrambling by gedunin. Cell Physiol Biochem. 2014; 33: 1838-1848.
35. Zhang R, Xiang Y, Ran Q, Deng X, Xiao Y, Xiang L, Li Z. Involvement of calcium, reactive oxygen species, and ATP in hexavalent chromium-induced damage in red blood cells. Cell Physiol Biochem. 2014; 34: 1780-1791.
36. Lang E, Jilani K, Bissinger R, Rexhepaj R, Zelenak C, Lupescu A, Lang F, Qadri SM. Vitamin D-Rich Diet in Mice Modulates Erythrocyte Survival. Kidney Blood Press Res. 2015; 40: 403-412.
37. Risso A, Ciana A, Achilli C, Minetti G. Survival and senescence of human young red cells in vitro. Cell Physiol Biochem. 2014; 34: 1038-1049.
38. Bouguerra G, Bissinger R, Abbes S, Lang F. Zopolrestat Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem. 2015; 37: 1537-1546.
39. Faggio C, Alzoubi K, Calabro S, Lang F. Stimulation of suicidal erythrocyte death by PRIMA-1. Cell Physiol Biochem. 2015; 35: 529-540.
40. Peter T, Bissinger R, Enkel S, Alzoubi K, Oswald G, Lang F. Programmed erythrocyte death following in vitro Treosulfan treatment. Cell Physiol Biochem. 2015; 35: 1372-1380.
41. Pagano M, Faggio C. The use of erythrocyte fragility to assess xenobiotic cytotoxicity. Cell Biochem Funct. 2015; 33: 351-355.
42. Bissinger R, Modicano P, Alzoubi K, Honisch S, Faggio C, Abed M, Lang F. Effect of saponin on erythrocytes. Int J Hematol. 2014; 100: 51-59.
43. Lang E, Modicano P, Arnold M, Bissinger R, Faggio C, Abed M, Lang F. Effect of thioridazine on erythrocytes. Toxins (Basel). 2013; 5: 1918-1931.
44. Bissinger R, Bouguerra G, Stockinger K, Abbes S, Lang F. Triggering of Suicidal Erythrocyte Death by Topotecan. Cell Physiol Biochem. 2015; 37: 1607-1618.
45. Mahmud H, Foller M, Lang F. Suicidal erythrocyte death triggered by cisplatin. Toxicology. 2008; 249: 40-44.
46. Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev. 2015; 8: CD006849.
47. Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F. Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol. 2012; 302: C644-C651.
48. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol. 2007; 27: 414-421.
49. Franchini M, Mannucci PM. Low-molecular-weight heparins and cancer: focus on antitumoral effect. Ann Med. 2015; 47: 116-121.
50. Vitale C, D'Amato M, Calabro P, Stanziola AA, Mormile M, Molino A. Venous thromboembolism and lung cancer: a review. Multidiscip Respir Med. 2015; 10: 28.
51. Debeljak N, Solar P, Sytkowski AJ. Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol. 2014; 5: 563.